XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
We received from XORTX Therapeutics Inc. amd we are glad to publish the following press release: "XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of…